SuspendedPhase 1NCT00909558
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Studying Squamous cell carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Envita Medical Center, Inc.
- Principal Investigator
- David Korn, D.O., M.D.Envita Medical Centers
- Intervention
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy(biological)
- Enrollment
- 24 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2009
Study locations (1)
- Envita Medical Centers, Scottsdale, Arizona, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00909558 on ClinicalTrials.govOther trials for Squamous cell carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07172802A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid TumorsGI Innovation, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05945823Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsTaiho Oncology, Inc.